Catalyst Wire Dossier Catalyst Wire Dossier

FMX103 1.5% topical minocycline foam

minocycline · Vyne Therapeutics Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for FMX103 1.5% topical minocycline foam, covering 2020-12-16 to 2020-12-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea [Phase 3]

See pricing